Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UTD1 plus capecitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| UTD1 Injection plus capecitabine | EXPERIMENTAL | UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. |
| capecitabine | ACTIVE_COMPARATOR | Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. |
| Name | Type | Description |
|---|---|---|
| UTD1 Injection plus capecitabine | DRUG | - |
| Capecitabine | DRUG | - |
Inclusion Criteria: 1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy; 2. Patients who have previously treated with ≤4 chemotherapeutic regimes; 3. Patients who have pr...
Top 20 of 84 competitors